Page 2,768«..1020..2,7672,7682,7692,770..2,7802,790..»

Successful Stem Cell Differentiation Requires DNA Compaction

Posted: May 11, 2012 at 6:14 pm

Newswise New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.

Researchers from the Georgia Institute of Technology and Emory University found that chromatin compaction is required for proper embryonic stem cell differentiation to occur. Chromatin, which is composed of histone proteins and DNA, packages DNA into a smaller volume so that it fits inside a cell.

A study published on May 10, 2012 in the journal PLoS Genetics found that embryonic stem cells lacking several histone H1 subtypes and exhibiting reduced chromatin compaction suffered from impaired differentiation under multiple scenarios and demonstrated inefficiency in silencing genes that must be suppressed to induce differentiation.

While researchers have observed that embryonic stem cells exhibit a relaxed, open chromatin structure and differentiated cells exhibit a compact chromatin structure, our study is the first to show that this compaction is not a mere consequence of the differentiation process but is instead a necessity for differentiation to proceed normally, said Yuhong Fan, an assistant professor in the Georgia Tech School of Biology.

Fan and Todd McDevitt, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, led the study with assistance from Georgia Tech graduate students Yunzhe Zhang and Kaixiang Cao, research technician Marissa Cooke, and postdoctoral fellow Shiraj Panjwani.

The work was supported by the National Institutes of Healths National Institute of General Medical Sciences (NIGMS), the National Science Foundation, a Georgia Cancer Coalition Distinguished Scholar Award, and a Johnson & Johnson/Georgia Tech Healthcare Innovation Award.

To investigate the impact of linker histones and chromatin folding on stem cell differentiation, the researchers used embryonic stem cells that lacked three subtypes of linker histone H1 -- H1c, H1d and H1e -- which is the structural protein that facilitates the folding of chromatin into a higher-order structure. They found that the expression levels of these H1 subtypes increased during embryonic stem cell differentiation, and embryonic stem cells lacking these H1s resisted spontaneous differentiation for a prolonged time, showed impairment during embryoid body differentiation and were unsuccessful in forming a high-quality network of neural cells.

This study has uncovered a new, regulatory function for histone H1, a protein known mostly for its role as a structural component of chromosomes, said Anthony Carter, who oversees epigenetics grants at NIGMS. By showing that H1 plays a part in controlling genes that direct embryonic stem cell differentiation, the study expands our understanding of H1s function and offers valuable new insights into the cellular processes that induce stem cells to change into specific cell types.

During spontaneous differentiation, the majority of the H1 triple-knockout embryonic stem cells studied by the researchers retained a tightly packed colony structure typical of undifferentiated cells and expressed high levels of Oct4 for a prolonged time. Oct4 is a pluripotency gene that maintains an embryonic stem cells ability to self-renew and must be suppressed to induce differentiation.

H1 depletion impaired the suppression of the Oct4 and Nanog pluripotency genes, suggesting a novel mechanistic link by which H1 and chromatin compaction may mediate pluripotent stem cell differentiation by contributing to the epigenetic silencing of pluripotency genes, explained Fan. While a significant reduction in H1 levels does not interfere with embryonic stem cell self-renewal, it appears to impair differentiation.

Read the original here:
Successful Stem Cell Differentiation Requires DNA Compaction

Posted in Stem Cells | Comments Off on Successful Stem Cell Differentiation Requires DNA Compaction

Successful stem cell differentiation requires DNA compaction, study finds

Posted: May 11, 2012 at 6:14 pm

ScienceDaily (May 11, 2012) New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.

Researchers from the Georgia Institute of Technology and Emory University found that chromatin compaction is required for proper embryonic stem cell differentiation to occur. Chromatin, which is composed of histone proteins and DNA, packages DNA into a smaller volume so that it fits inside a cell.

A study published on May 10, 2012 in the journal PLoS Genetics found that embryonic stem cells lacking several histone H1 subtypes and exhibiting reduced chromatin compaction suffered from impaired differentiation under multiple scenarios and demonstrated inefficiency in silencing genes that must be suppressed to induce differentiation.

"While researchers have observed that embryonic stem cells exhibit a relaxed, open chromatin structure and differentiated cells exhibit a compact chromatin structure, our study is the first to show that this compaction is not a mere consequence of the differentiation process but is instead a necessity for differentiation to proceed normally," said Yuhong Fan, an assistant professor in the Georgia Tech School of Biology.

Fan and Todd McDevitt, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, led the study with assistance from Georgia Tech graduate students Yunzhe Zhang and Kaixiang Cao, research technician Marissa Cooke, and postdoctoral fellow Shiraj Panjwani.

The work was supported by the National Institutes of Health's National Institute of General Medical Sciences (NIGMS), the National Science Foundation, a Georgia Cancer Coalition Distinguished Scholar Award, and a Johnson & Johnson/Georgia Tech Healthcare Innovation Award.

To investigate the impact of linker histones and chromatin folding on stem cell differentiation, the researchers used embryonic stem cells that lacked three subtypes of linker histone H1 -- H1c, H1d and H1e -- which is the structural protein that facilitates the folding of chromatin into a higher-order structure. They found that the expression levels of these H1 subtypes increased during embryonic stem cell differentiation, and embryonic stem cells lacking these H1s resisted spontaneous differentiation for a prolonged time, showed impairment during embryoid body differentiation and were unsuccessful in forming a high-quality network of neural cells.

"This study has uncovered a new, regulatory function for histone H1, a protein known mostly for its role as a structural component of chromosomes," said Anthony Carter, who oversees epigenetics grants at NIGMS. "By showing that H1 plays a part in controlling genes that direct embryonic stem cell differentiation, the study expands our understanding of H1's function and offers valuable new insights into the cellular processes that induce stem cells to change into specific cell types."

During spontaneous differentiation, the majority of the H1 triple-knockout embryonic stem cells studied by the researchers retained a tightly packed colony structure typical of undifferentiated cells and expressed high levels of Oct4 for a prolonged time. Oct4 is a pluripotency gene that maintains an embryonic stem cell's ability to self-renew and must be suppressed to induce differentiation.

"H1 depletion impaired the suppression of the Oct4 and Nanog pluripotency genes, suggesting a novel mechanistic link by which H1 and chromatin compaction may mediate pluripotent stem cell differentiation by contributing to the epigenetic silencing of pluripotency genes," explained Fan. "While a significant reduction in H1 levels does not interfere with embryonic stem cell self-renewal, it appears to impair differentiation."

Read the original here:
Successful stem cell differentiation requires DNA compaction, study finds

Posted in Stem Cells | Comments Off on Successful stem cell differentiation requires DNA compaction, study finds

New Teva Representative Joins Mesoblast Board of Directors

Posted: May 11, 2012 at 6:13 pm

MELBOURNE, Australia, May 10, 2012 /PRNewswire/ -- Global regenerative medicine company Mesoblast Limited (MSB.AX) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, as a non-executive Director of Mesoblast, effective immediately.

Dr Weiner has been Teva's head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee. In this role, he has directly overseen all pharmaceutical R&D and innovative branded product pipeline development.

Dr Weiner has been responsible for the development of hundreds of generic products for the US, EU and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva's innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis.

Dr Weiner said: "I am happy and proud to be a Board member of Mesoblast. I trust that stem cell technology is the future of medicine, and that Mesoblast is at the cutting edge of this exciting new field.

"I believe that Mesoblast's unique technology and professional execution capabilities have the potential to deliver multiple innovative biologic products across a broad range of clinical indications," added Dr Weiner.

Mesoblast Chairman, Mr Brian Jamieson, said: "Dr Weiner's extensive pharmaceutical industry experience and his current role as Special Adviser to the Teva CEO make him a very valuable and strategic addition to the Board. We also acknowledge the important contributions and insights provided by Teva's retiring board representative, Kevin Buchi, and wish him well.

"As Mesoblast expands its clinical product portfolio and approaches product commercialization, we will continue to broaden the mix of skills and international expertise of our Directors to ensure that the Board is in the best position to deliver maximal shareholder value."

About Mesoblast Mesoblast Limited (MSB.AX) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). http://www.mesoblast.com

For further information, please contact: Julie Meldrum Corporate Communications Mesoblast Limited E: julie.meldrum@mesoblast.com

See the rest here:
New Teva Representative Joins Mesoblast Board of Directors

Posted in Regenerative Medicine | Comments Off on New Teva Representative Joins Mesoblast Board of Directors

Genetic packing: Successful stem cell differentiation requires DNA compaction, study finds

Posted: May 11, 2012 at 6:13 pm

Hematoxylin and eosin (H&E) staining of sections of wild-type (top row) and H1 triple-knockout (bottom row) embryoid bodies. After 14 days in rotary suspension culture, the wild-type embryoid bodies showed more differentiated morphologies with cysts forming (black arrows) and the knockout embryoid bodies failed to form cavities (far right). (Credit: Yuhong Fan)

(Phys.org) -- New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.

Researchers from the Georgia Institute of Technology and Emory University found that chromatin compaction is required for proper embryonic stem cell differentiation to occur. Chromatin, which is composed of histone proteins and DNA, packages DNA into a smaller volume so that it fits inside a cell.

A study published on May 10, 2012 in the journal PLoS Genetics found that embryonic stem cells lacking several histone H1 subtypes and exhibiting reduced chromatin compaction suffered from impaired differentiation under multiple scenarios and demonstrated inefficiency in silencing genes that must be suppressed to induce differentiation.

While researchers have observed that embryonic stem cells exhibit a relaxed, open chromatin structure and differentiated cells exhibit a compact chromatin structure, our study is the first to show that this compaction is not a mere consequence of the differentiation process but is instead a necessity for differentiation to proceed normally, said Yuhong Fan, an assistant professor in the Georgia Tech School of Biology.

Fan and Todd McDevitt, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, led the study with assistance from Georgia Tech graduate students Yunzhe Zhang and Kaixiang Cao, research technician Marissa Cooke, and postdoctoral fellow Shiraj Panjwani.

The work was supported by the National Institutes of Healths National Institute of General Medical Sciences (NIGMS), the National Science Foundation, a Georgia Cancer Coalition Distinguished Scholar Award, and a Johnson & Johnson/Georgia Tech Healthcare Innovation Award.

Enlarge

Phase contrast images showing that H1 triple-knockout (bottom) embryonic stem cells were unable to adequately form neurites and neural networks compared to wild-type embryonic stem cells (top). (Click image for high-resolution version. Credit: Yuhong Fan)

Enlarge

More here:
Genetic packing: Successful stem cell differentiation requires DNA compaction, study finds

Posted in Genetic Engineering | Comments Off on Genetic packing: Successful stem cell differentiation requires DNA compaction, study finds

Now *This* Is a Cell Phone: Using Radio Waves to Control Specific Genes in Mice | 80beats

Posted: May 11, 2012 at 6:13 pm

With some clever genetic engineering but without ever touching a cell or an animal, scientist can remotely control cells using ultrasound, light,and, now, also radio waves. The electromagnetic waves can be used to selectivelyheat up parts of cells and activate a gene to make insulin in mice, according to a recent study published in Science.

But why care about radio waves if we have light and ultrasound?Radio waves have a couple distinct advantages over existing techniques.

In the current study, the radio waves didnt heat up a whole patch of tissue or even a whole cellit only affected specific pores in the cell, calledTRPV1,that open in response to heat. To get this specificity, the scientists made special iron oxide nanoparticles attached to an antibody that only sticks to TRPV1. When they turned on the radio waves, the iron oxide particles warmed up and opened the TRPV1 channel, minimally affecting the rest of the cell or surrounding cells.Ultrasound, on the other hand, heats up a whole patch of tissue to 42 Celsius, which could have damaging or confounding effects on the cells.

Radio waves, unlike light, can also penetrate deep into tissue. To show how the radio could safely work inside an animal, scientists injected mice with special cells that had been genetically engineered to include both the TRPV1 pore and a gene switch that would release insulin when exposed to calcium. Then they got those cells in the mice to start making insulin with a little Rube Goldberg-esque cellular machine: heat from the radio waves opened the TRPV1 channels, calcium rushed into the cells through the open TRPV1, the flood of calcium turned on the insulin gene switch, and, finally, the cells began making insulin. (The whole chain of events makes you appreciate the complexity of biology, right?)

In one last step, the scientists did away with the synthetic iron oxide nanoparticles altogther. They got cells to produce their own iron nanoparticles, a iron storage protein calledferritin. When they tested ferritin in cells, it was 2/3 as effective at inducing insulin production as the synthetic nanoparticles.

There could be medical applications for activating genes in stem cell therapy in the future, but for now, this is just pretty cool: scientists can turn on some radio waves and hack right into the cellular machinery of a mouse.

[via Nature News]

Mouse image via Shutterstock / lculig

View post:
Now *This* Is a Cell Phone: Using Radio Waves to Control Specific Genes in Mice | 80beats

Posted in Genetic Engineering | Comments Off on Now *This* Is a Cell Phone: Using Radio Waves to Control Specific Genes in Mice | 80beats

Julio C. Voltarelli, Pioneer in Cell Transplantation, Dies at 63

Posted: May 11, 2012 at 6:12 pm

Dr. Julio C. Voltarelli, who made a significant impact in cell transplantation, dies at 63

Distinguished Brazilian professor pioneered bone marrow transplantation

Newswise Tampa, Fla. (May. 9th , 2012) Julio C. Voltarelli, MD, PhD, professor at the Ribeiro Preto School of Medicine at the University of So Paulo, Brazil, died March 21, 2012 at the age of 63. Dr. Voltarelli, who was on the editorial board of the Cell Transplantation journal, published by Cognizant Communication Corporation, and an important factor in the journals success, was a distinguished stem cell researcher and head of the bone marrow transplantation unit at the Ribeiro Preto School of Medicine.

Dr. Voltarelli had a significant impact on Brazilian stem cell transplantation science, said Dr. Maria C. O. Rodrigues, Dr. Voltarellis longtime colleague. He was driven to bring the benefits of the newest cellular therapies to those with ALS, MS and type 1 diabetes. His efforts and dedication will be greatly missed.

Dr. Voltarelli, a graduate of the Ribeiro Preto School of Medicine, served post-doctoral fellowships at the University of California San Francisco, the Fred Hutchinson Cancer Research Center in Seattle, and the Scripps Research Institute in San Diego. He returned to Brazil in 1992 and started a highly ranked bone marrow transplantation program at the Ribeiro Preto School of Medicine. In 2002, Dr. Voltarelli initiated the schools research efforts in stem cell transplantation for autoimmune diseases, later focusing on diabetes, graft-versus-host disease and sickle cell anemia.

At the time of his death, Dr. Voltarelli, in addition to serving as head of the bone marrow transplantation unit, also served as research coordinator for the Center for Cellular Therapy at the So Paulo Research Foundation and the National Institute of Science and Technology in Stem Cells and Cell Therapy. He was recently elected president of the Brazilian Society of Bone Marrow Transplantation.

His publications included the first books on stem cell transplantation and clinical immunology written in Portuguese. He also founded the Brazilian Society of Stem Cell Transplantation.

His colleagues in Brazil called his lifelong contributions priceless and remembered him for his leadership skills, vision, and sense of humor.

# The Coeditor-in-chiefs for CELL TRANSPLANTATION are at the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan, and the Diabetes Research Institute, University of Miami Miller School of Medicine. Contact, Shinn-Zong Lin, MD, PhD at shinnzong@yahoo.com.tw or Camillo Ricordi, MD at ricordi@miami.edu or David Eve, PhD at celltransplantation@gmail.com #

News release by Florida Science Communications http://www.sciencescribe.net

Read the original here:
Julio C. Voltarelli, Pioneer in Cell Transplantation, Dies at 63

Posted in Cell Medicine | Comments Off on Julio C. Voltarelli, Pioneer in Cell Transplantation, Dies at 63

Regenerative medicine: Could the ways animals regenerate hair and feathers help restore human fingers and toes?

Posted: May 11, 2012 at 6:12 pm

ScienceDaily (May 10, 2012) This summer's action film, "The Amazing Spider-Man," is another match-up between the superhero and his nemesis the Lizard. Moviegoers and comic book fans alike will recall that the villain, AKA Dr. Curt Connors, was a surgeon who, after losing an arm, experimented with cell generation and reptilian DNA and was eventually able to grow back his missing limb.

The latest issue of the journal Physiology contains a review article that looks at possible routes that unlock cellular regeneration in general, and the principles by which hair and feathers regenerate themselves in particular.

The authors apply what is currently known about regenerative biology to the emerging field of regenerative medicine, which is being transformed from fantasy to reality.

Review Article

While the concept of regenerative medicine is relatively new, animals are well known to remake their hair and feathers regularly by normal regenerative physiological processes. In their review, the authors focus on (1) how extrafollicular environments can regulate hair and feather stem cell activities and (2) how different configurations of stem cells can shape organ forms in different body regions to fulfill changing physiological needs.

The review outlines previous research on the role of normal regeneration of hair and feathers throughout the lifespan of various birds and mammals. The researchers include what is currently known about the mechanism behind this re-growth, as well as what gaps still exist in the knowledge base and remain ripe for future research.

The review examines dozens of papers on normal "physiological regeneration" -- the re-growth that happens over the course of an animal's life and not in response to an injury. This regeneration takes place to accommodate different stages in an animal's life (e.g., replacing downy chick feathers with an adult chicken's, or replacing the fine facial hair of a young boy with the budding beard of an adolescent), or in response to various environmental conditions (e.g., cats shedding a thick winter coat in the summer heat but re-growing it when the seasons change again, or snowshoe hares switching from brown in the summer to white in the winter for camouflage).

These changes seem to respond both to internal cues such as physiology of the hair follicle itself, or external cues such as the environment, but the mechanisms behind these normal alterations are largely unknown. Stem cells inside the follicle prompt hair and feather regeneration, but researchers are still unsure how to guide those cells to form the shape, size, and orientation of these "skin appendages" so that controlled re-growth is possible. Additionally, scientists are still unsure how to re-grow hair on skin in people after severe injuries that lead to scar tissue.

Importance of the Findings

The reviewed studies suggest that while researchers are making headway in understanding how and why hair and feathers regenerate after normal loss or in response to different life stages, much still remains unknown. This missing knowledge could hold valuable clues to learning how to regenerate much more complicated and valuable structures after loss to injury, such as fingers and toes.

Excerpt from:
Regenerative medicine: Could the ways animals regenerate hair and feathers help restore human fingers and toes?

Posted in Cell Medicine | Comments Off on Regenerative medicine: Could the ways animals regenerate hair and feathers help restore human fingers and toes?

New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly …

Posted: May 11, 2012 at 6:12 pm

BOUDRY, Switzerland--(BUSINESS WIRE)--

Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG - News), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine. All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas.

Continuous Lenalidomide Therapy (non-transplant eligible population):

The first article highlights a Celgene-sponsored study of continuous lenalidomide treatment in elderly patients newly diagnosed with multiple myeloma.

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015)

This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalanprednisonelenalidomide induction followed by lenalidomide maintenance (MPR-R), with melphalanprednisonelenalidomide (MPR), or melphalanprednisone (MP) followed by placebo in 459 patients aged 65 years with newly-diagnosed myeloma who were not eligible for autologous stem-cell transplant.

http://www.nejm.org/doi/full/10.1056/NEJMoa1112704

Post-transplant maintenance

The two additional articles published in the edition highlighted cooperative group studies that evaluated the use of lenalidomide maintenance following autologous stem cell transplant (ASCT).

In each of the studies, one funded by the National Cancer Institute and conducted by the Cancer and Leukemia Group B (CALGB) and one by the Intergroupe Francophone du Myelome (IFM), maintenance treatment with lenalidomide following ASCT resulted in delayed time to disease progression or death compared to placebo.

See the article here:
New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly ...

Posted in Cell Medicine | Comments Off on New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly …

ALS Patients Approved For More Stem Cells

Posted: May 10, 2012 at 11:11 pm

University of Michigan Hospital (Credit: UM.edu)

ANN ARBOR Three patients with amyotrophic lateral sclerosis will be permitted to receive a second dose of stem cells delivered directly to the spinal cord, in a clinical trial being led by the University of Michigans Eva Feldman, M.D.

The U.S. Food and Drug Administration approved the second treatment after a review concluded that the patients showed no adverse effects from their first implantation surgeries.

All have ALS, the inevitably fatal degenerative disease of the nervous system that many call Lou Gehrigs disease. They received injections directly into the lumbar, or lower, area of the spinal cord.

None of the patients experienced any long-term complications related to either the surgical procedure or the implantation of stem cells, or showed signs of rejecting the cells. And in the months following the surgery to inject the cells, none showed evidence that their ALS progression was accelerating.

These patients will receive a second implantation to the cervical, or upper, region of the spine where the nerves that control breathing reside. Most ALS patients die of respiratory failure as these nerves die or are damaged by the disease.

We believe that the cells and the route of administration are safe, said Feldman, principal investigator of the trial and the director of the UMs A. Alfred Taubman Medical Research Institute. The FDA go-ahead to bring these three patients back for re-dosing is a further validation of that.

The trial is funded by Neuralstem, to which Feldman is an unpaid consultant.

This Phase 1 safety trial, which is taking place at Emory University in Atlanta, began in January 2010. After reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance the cervical injections. Three patients so far have received injections to that area. Those to be re-dosed will come from the first cohort of 12.

Results from that cohort recently were featured in the peer-reviewed journal Stem Cells in an article authored by Feldman and her colleagues at Emory, including neurologist Jonathan Glass, M.D. and neurosurgeon Nick Boulis, M.D., who performed the implantation surgeries. Boulis, an adjunct professor at UMs Medical School and a Taubman Scholar, also developed the device used to inject the stem cells into the spinal cord, which received a notice of patent allowance from U.S. Patent and Trademark Office in October.

Go here to read the rest:
ALS Patients Approved For More Stem Cells

Posted in Stem Cell Videos | Comments Off on ALS Patients Approved For More Stem Cells

Stem cells jab 'helps brain cancer patients tolerate chemotherapy'

Posted: May 10, 2012 at 11:11 pm

By Daily Mail Reporter

PUBLISHED: 16:01 EST, 9 May 2012 | UPDATED: 01:37 EST, 10 May 2012

Stem cells have been transplanted into brain cancer patients for the first time in a bid to protect them against the toxic side effects of chemotherapy.

In a study involving three patients, scientists found that two of them survived longer than predicted following the surgery while the other has seen no disease progression after three years of treatment.

The study was carried out by the Fred Hutchinson Cancer Research Centre in the United States.

Breakthrough: Scientists have transferred stem cells into brain cancer sufferers in a bid to protect them against the harmful effects of chemotherapy

The centre's Dr Hans-Peter Kiem said: 'We found that patients were able to tolerate the chemotherapy better and without negative side effects after transplantation of the gene-modified stem cells.

'This compares with patients in previous studies who received the same type of chemotherapy without a transplant of gene-modified stem cells.'

Dr Kiem added that a major barrier to effective use of chemotherapy to treat cancers such as glioblastoma, which all three patients had, has been the toxicity of chemotherapy drugs to other organs, primarily bone marrow.

This results in decreased blood cell counts, increased susceptibility to infections and other side effects.

Go here to see the original:
Stem cells jab 'helps brain cancer patients tolerate chemotherapy'

Posted in Stem Cell Videos | Comments Off on Stem cells jab 'helps brain cancer patients tolerate chemotherapy'

Page 2,768«..1020..2,7672,7682,7692,770..2,7802,790..»